Evidence map›Paper›PMID 22194833›Full record

ArticlePloS one2011

Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer.

Georgios Deftereos, Simon R Corrie, Qinghua Feng, Janice Morihara, Joshua Stern, Stephen E Hawes, Nancy B Kiviat

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 4 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. [Estrogen, estrogen receptor and miR-21 in adenomyosis: their pathogenic roles and regulatory interactions].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. MicroRNA replacement therapy in cancer.Journal of cellular physiology · 2019
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Georgios DeftereosHPV Research Laboratory, UW Medicine, University of Washington, Seattle, Washington, United States of America.
Simon R Corrie
Qinghua Feng
Janice Morihara
Joshua Stern
Stephen E Hawes
Nancy B Kiviat
University of Washington · US

Funding

Chlamydia & Aberrant DNA Methylation in Cervical CancerR01CA115713 · NCI · UNIVERSITY OF WASHINGTON · PI KIVIAT, NANCY B. · 2006 to 2010
$2.5M
EPIDEMIOLOGY &BIOLOGY OF HIV+ AND--CERVICAL NEOPLASIAR01CA075920 · NCI · UNIVERSITY OF WASHINGTON · PI KIVIAT, NANCY B. · 1997 to 2001
$929k
NCI NIH HHS R01 CA115713NCI NIH HHS R01 CA75920
6 · The paper itself

Abstract

backgroundMicroRNA expression is severely disrupted in carcinogenesis, however limited evidence is available validating results from cell-line models in human clinical cancer specimens. MicroRNA-21 (mir-21) and microRNA-143 (mir-143) have previously been identified as significantly deregulated in a range of cancers including cervical cancer. Our goal was to investigate the expression patterns of several well-studied microRNA species in cervical samples and compare the results to cell line samples. METHODOLOGY/PRINCIPAL

findingsWe measured the expression of mir-21 and mir-143 in 142 formalin-fixed, paraffin embedded (FFPE) cervical biopsy tissue blocks, collected from Dantec Oncology Clinic, Dakar, Senegal. MicroRNA expression analysis was performed using Taqman-based real-time PCR assays. Protein immunohistochemical staining was also performed to investigate target protein expression on 72 samples. We found that mir-21 expression increased with worsening clinical diagnosis but that mir-143 was not correlated with histology. These observations were in stark contrast to previous reports involving cervical cancer cell lines in which mir-143 was consistently down-regulated but mir-21 largely unaffected. We also identified, for the first time, that cytoplasmic expression of Programmed Cell Death Protein 4 PDCD4; a known target of mir-21) was significantly lower in women with invasive cervical carcinoma (ICC) in comparison to those with cervical intraepithelial neoplasia (2-3) or carcinoma in situ (CIN2-3/CIS), although there was no significant correlation between mir-21 and PDCD4 expression, despite previous studies identifying PDCD4 transcript as a known mir-21 target.

conclusionsWhilst microRNA biomarkers have a number of promising features, more studies on expression levels in histologically defined clinical specimens are required to investigate clinical relevance of discovery-based studies. Mir-21 may be of some utility in predictive screening, given that we observed a significant correlation between mir-21 expression level and worsening histological diagnosis of cervical cancer.

Indexed as

Gene Expression Regulation, NeoplasticCell Line, TumorCervix UteriFemaleFormaldehydeGene Expression ProfilingGenes, NeoplasmHumansImmunohistochemistryMicroRNAsNeoplasm InvasivenessNeoplasm ProteinsParaffin EmbeddingTissue FixationUterine Cervical NeoplasmsFormaldehydeMicroRNAsMIRN143 microRNA, humanMIRN21 microRNA, humanNeoplasm Proteins

Identifiers

PMID22194833
PMCPMC3237431
OpenAlexW1997779566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.